Iressa (Gefitinib) for Lung Cancer | MyLungCancerTeam

Connect with others who understand.

sign up Log in
About MyLungCancerTeam
Powered By

Iressa is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat metastatic, non-small cell lung cancer whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 substitution mutations as detected by an FDA-approved test. Iressa is also referred to by its drug name, gefitinib.

Iressa is a member of a class of drugs called tyrosine kinase inhibitors. Gilotrif is believed to work by inhibiting mutated EGFR, a kinase (protein) involved in cancer cell proliferation, thereby slowing the growth and spread of tumors.

How do I take it?
Prescribing information states that Iressa is taken orally as a tablet once daily, with or without food.

Iressa should be taken exactly as prescribed by a physician.

Side effects
The FDA-approved label for Iressa lists common side effects including skin reactions and diarrhea.

Rare but serious side effects listed for Iressa include eye disorders, liver damage, stomach and intestinal damage, fetal harm, and interstitial lung disease (scarring of the lungs).

For more details about this treatment, visit:

Highlights of Prescribing Information — U.S. Food and Drug Administration

Gefitinib (Oral Route) — Mayo Clinic

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in